Funding for this research was provided by:
Takeda Pharmaceuticals U.S.A.
Article History
Received: 6 July 2020
Accepted: 7 July 2021
First Online: 5 August 2021
Declarations
:
: In accordance with the Good Practice Secondary Data Analysis (GPS) guidelines, ethical committee review nor informed consent was not required as it does not apply to secondary data analyses, provided that all the data protection provisions on pseudo-anonymization of personal data are fulfilled and no link to primary data is intended.
: Not applicable.
: ENC, TC and TV received financial support through contract services to P95 Pharmacovigilance and Epidemiology from Takeda Vaccines Inc., Deerfield, IL (a corporation undertaking commercial development of a norovirus vaccine). The investigators were responsible for the study design, data collection and analysis, as well as the interpretation of findings, report and manuscript writing and the decision to submit the paper for publication.